3 news items
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
VIR
13 May 24
rationales in the development of functional cure combination regimens for patients with chronic HBV infection," said Dr. Qing Zhu, Head of China R
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
ANTX
VBIV
VIR
22 Mar 24
Integrating R&D, manufacturing and commercial upsides by acquiring full
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
VIR
22 Feb 24
:
Closing R&D facilities in St. Louis, Missouri and Portland, Oregon in 2024. Research
- Prev
- 1
- Next